{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"31","upperLimit":"31","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"description":"Donor CD3 chimerism less than 5%","groups":[{"description":"Patients receive fludarabine phosphate IV on days -4 to -2. Patients then undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.\n\ntotal-body irradiation: Undergo TBI\n\nfludarabine phosphate: Given IV\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given PO\n\nperipheral blood stem cell transplantation: Undergo transplantation","id":"OG000","title":"Arm I (Chemotherapy, TBI, Transplant, GVHD Prophylaxis)"},{"description":"Patients undergo low-dose TBI on day 0. After TBI, patients undergo PBSCT on day 0. Patients receive cyclosporine PO BID on days -3 to 56 in the absence of GVHD. Patients with no evidence of GVHD at day 56 begin a cyclosporine taper and continue the taper until day 180. Patients with evidence of disease progression and no evidence of GVHD prior to day 56 receive tapered doses of cyclosporine for 2 weeks. Patients also receive MMF PO BID on days 0-28 in the absence of GVHD. If treatment for GVHD is required before day 28, MMF is continued until a steroid taper begins.\n\ntotal-body irradiation: Undergo TBI\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given PO\n\nperipheral blood stem cell transplantation: Undergo transplantation","id":"OG001","title":"Arm II (TBI, Transplant, GVHD Prophylaxis)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year after transplant","title":"Incidence of Graft Rejection","type":"SECONDARY","unitOfMeasure":"participants"}